Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

p> Therapeutics Inc. - - 2,156,685

Gain on sale of BCY

LifeSciences Inc. - - (299,403)

Cancellation of contingent

payment obligation settled

in common shares - - 150,000

Future income tax recovery - - (1,115,000)

-------------------------------------------------------------------------

- - 1,383,537

-------------------------------------------------------------------------

-------------------------------------------------------------------------

6. CAPITAL DISCLOSURES

The Company's objective when managing capital is to maintain adequate

cash resources to support planned activities which include the clinical

trial program, product manufacturing, administrative costs and

intellectual property expansion and protection. The Company includes

shareholders' equity, cash and short-term investments in the definition

of capital. The Company does not have any debt other than trade accounts

payable and has potential contingent obligations relating to the

completion of its research and development of REOLYSIN(R).

In managing capital, the Company estimates its future cash requirements

by preparing a budget and a multiyear plan annually for review and

approval by the Company's board of directors (the "Board"). The budget

establishes the approved activities for the upcoming year and estimates

the costs associated with these activities. The multiyear plan estimates

future activity along with the potential cash requirements and is based

on the Company's assessment of its current clinical trial progress along

with the expected results from the coming year's activity. Budget to

actual variances are prepar
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014 Whitehouse Laboratories is ... the Morris County (New Jersey) Chamber of Commerce ... leading business organization in the North Jersey area, ... engage some key clients in the pharmaceutical and ... geographic area. Membership enables Whitehouse Laboratories a higher ...
(Date:11/26/2014)... 25, 2014 Continuing its award-winning streak, ... three prestigious MarCom Awards for outstanding creative achievement by ... Platinum MarCom Award, the organization’s top honor, in the ... Louis held in April of this year. The event ... attendees. Additionally, Nerium was awarded a Gold MarCom Award ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 Miles Holder, ... joined the Graphel Carbon Products team as Sales/Marketing Manager. ... marketing, and customer service for the graphite industry. , ... to our team,” stated Dave Trinkley, VP of Market ... wide range of experience in the graphite industry, along ...
(Date:11/26/2014)... November 26, 2014 2014 Deep ... an in-depth research report on the Global Palmitic ... introduces Palmitic Acid, basic information, including definition, classification, ... and news analysis, etc. , For international ... Palmitic Acid market in China and other ...
Breaking Biology Technology:Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3
... (NYSE Amex: PTN ), a biopharmaceutical company developing ... and other indications, today announced results for its third quarter ... Following a meeting with the U.S. ... to the FDA for initiation of an at-home Phase 2 ...
... InterMune, Inc. (Nasdaq: ITMN ) today announced ... demonstrating that treatment with pirfenidone, a novel antifibrotic and ... function, 6-minute walk test distance and progression-free survival (PFS) ... (IPF).  IPF is a rare and fatal lung disease ...
... 2011 Novavax, Inc. (Nasdaq: NVAX ) a ... Officer of Novavax, will be presenting at the NOBLE FINANCIAL ... at The Hard Rock Hotel, Hollywood, FL.  A live audio-only ... Company website at www.novavax.com under Investors/Events. ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 2Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 3Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 4Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 5Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 6Pirfenidone Phase 3 Results Published Today in The Lancet 2Pirfenidone Phase 3 Results Published Today in The Lancet 3Pirfenidone Phase 3 Results Published Today in The Lancet 4Pirfenidone Phase 3 Results Published Today in The Lancet 5Pirfenidone Phase 3 Results Published Today in The Lancet 6
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
(Date:11/3/2014)... low birth weight and preterm birth are linked to ... Findings published in the American College of Rheumatology (ACR) ... low birth weight and pre-term babies were not at ... adults. , According to the ACR, 27 million ... clinical OA. Symptoms of OA range from mild to ...
(Date:11/2/2014)... As a child, it was fascinating to put a ... shine through the hand. Washington University in St. Louis ... inside the body,s tissues to improve imaging of cancerous ... Wang, PhD, the Gene K. Beare Distinguished Professor of ... Science is applying a novel time-reversal technology that allows ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2Improving imaging of cancerous tissues by reversing time 2
... 2012As global temperatures rise, the most threatened ecosystems are those ... from the nation,s Long Term Ecological Research (LTER) Network ... is striking," says Julia Jones, a lead author in a ... featuring results from more than 30 years of LTER, a ...
... are the most populous organisms on the planet. They ... habitats by means of genetic variations that provide the ... what scientists believe is a random mutation and exchange ... that sometimes confers an advantage, and which then becomes ...
... of Illinois researchers surveyed over 3,500 college applicants, more than ... obese men were more likely to underestimate their weight than ... in dealing with a weight problem is knowing that you ... of food science and human nutrition. The study is ...
Cached Biology News:Long-term research reveals causes and consequences of environmental change 2Long-term research reveals causes and consequences of environmental change 3Long-term research reveals causes and consequences of environmental change 4Study shows unified process of evolution in bacteria and sexual eukaryotes 2Study shows unified process of evolution in bacteria and sexual eukaryotes 3Misperception of weight is an important barrier to weight loss 2
... for IVF are designed for human in ... of setup and operation, and convenience. ... continuously displayed on the control panel. Our ... printed by way of the thermal printer ...
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
... MultiScribe Reverse Transcriptase is a recombinant ... transcriptase. MultiScribe Reverse Transcriptase is similar ... in its recommended usage. MuLV reverse ... polymerase that uses single-stranded RNA as ...
... European Collection of Cell Cultures (ECACC) in ... of the West of England, Bristol, UK, ... quality control of HER2, oestrogen and progresterone ... wax sections of formalin fixed, breast cancer ...
Biology Products: